Amwell (NYSE: AMWL) reported Q1 EPS of ($0.25), $0.05 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $59.52 million versus the consensus estimate of $60.53 million.

GUIDANCE:

Amwell sees FY2024 revenue of $259-269 million, versus the consensus of $262 million.

Amwell sees FY2025 revenue of $335-350 million, versus the consensus of $322.5 million.

For earnings history and earnings-related data on Amwell (AMWL) click here.